VICTORIA, Feb. 21, 2019 /CNW/ – ImmunoPrecise Antibodies Ltd. (TSX:IPA)(OTC:IPATF)(FRA: TQB2) (the “Company” or “IPA”) has received a five-year Indefinite Delivery/Indefinite Quantity (ID/IQ) subcontract from Leidos Biomedical Research, Inc., which currently operates the Frederick National Laboratory for Cancer Research for the National Cancer Institute (NCI). Under the subcontract, IPA will discover and produce rabbit monoclonal antibodies using its proprietary B-Cell Select platform.
The rabbit monoclonal antibodies discovered and produced under this subcontract will be used in the key applications of immunohistochemistry and immuno-Multiple Reaction Monitoring (immune-MRM). The antibodies will be generated for NCI’s Antibody Characterization Program. Immuno-MRM is a leading-edge targeted mass spectrometry technique that relies on antibodies to enrich peptides from complex biological samples that are then quantified by mass spectrometry. Rabbit monoclonal antibodies are highly sought after for this purpose because they exhibit high specificity and bind their target with high affinity. Immuno-MRM is being used to discover novel biomarkers and develop a new generation of clinical diagnostic tests that could lead to improved cancer detection, diagnosis, and treatment.
IPA’s B-Cell Select platform enables rabbit monoclonal antibody discovery directly from B-cells through recombinant DNA cloning and expression of antibody gene sequences. This process allows for large panels of antibodies to be screened for functionality via multiple methods to pick the most relevant leads for the final application and can be applied to discover antibodies from several species for diagnostics and therapeutics.
“We are very pleased to work with Leidos Biomedical to support the world-class cancer research funded by NCI and NIH globally. We look forward to applying IPA’s experience and expertise in developing rabbit monoclonal antibodies to the challenging projects being advanced through Leidos” said Deanna Dryhurst, CSO of IPA.”
About Frederick National Laboratory for Cancer Research
The Frederick National Laboratory for Cancer Research is dedicated to improving human health through discovery and innovation in the biomedical sciences, focusing on cancer, AIDS, and rapid response to emerging infectious diseases. Frederick National Laboratory is operated by Leidos Biomedical Research, Inc. for the National Cancer Institute.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. (TSX:IPA)(OTC:IPATF)(FRA: TQB2) is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.
ImmunoPrecise operates from state-of-the-art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia, in collaboration with its wholly-owned subsidiary operations at U-Protein Express B.V., in the Life Science Incubator, Utrecht, and ModiQuest Research, Oss, both in the Netherlands. The Company operates globally to offer antibody services from target analysis to pre-clinical studies.
The services offered to clients include antibody discovery against a broad spectrum of antigens, including challenging targets. Amongst these services, the Company offers hybridoma production, B-cell services, and a variety of phage display platforms. The Company also provides a broad range of supporting services including immunologically-based assays, recombinant protein manufacturing, humanization, optimization, stable cell line development, and advanced solutions to challenges faced by clients in antibody-related research and development. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.
Forward-Looking Information
This news release contains statements that to the extent, they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. The Company uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend” and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions, and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise’s expectations and predictions is subject to any number of risks, assumptions, and uncertainties. Many factors could cause ImmunoPrecise’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise’s annual management discussion and analysis for the fiscal year ended April 30, 2017, which can be accessed at www.sedar.com. The “forward-looking statements” contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.
